Saturday 17 October 2026
Export CAPS’s income statement to Excel — free account
Capstone Therapeutics Corp.
CAPS Basic Materials Building Materials
Capstone Therapeutics Corp.’s revenue for fiscal 2025 (year ended December 2025) was $46.9 million, up 4.47% from fiscal 2024. In the quarter to June 2026, revenue grew 67.1%, EPS grew 15.4%, free cash flow grew 73.4% and total debt rose 45.9%, each against the same quarter a year earlier.
0.09
0.01
−10.00%
Follow CAPS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.17 | 0.08 | 0.12 | 0.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
0.00 | (9.25) | (2.24) | (8.10) | |
P/B ratio |
0.30 | 0.31 | 0.56 | 0.26 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.58 | 0.57 | 0.61 | 0.47 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(21.44) | (6.01) | (6.43) | (7.89) | |
EV/FCF |
(21.07) | (5.85) | (6.26) | (7.45) | |
Quick Ratio |
0.32 | 0.24 | 0.27 | 0.35 | |
Current Ratio |
0.95 | 1.00 | 0.95 | 0.99 | |
Net Debt/EBITDA |
(46.35) | (3.45) | (26.46) | 12.95 | |
Debt/Assets |
32.87% | 45.47% | 48.09% | 46.56% | |
Debt/Equity |
0.71 | 1.88 | 2.31 | 2.05 | |
Asset Turnover |
1.51 | 0.95 | 0.97 | 1.13 | |
Operating CF/Net income |
0.00 | 0.03 | 1.46 | 0.28 | |
Capex/Depreciation |
(0.04) | (0.07) | (0.05) | (0.04) | |
Interest Coverage |
(1.29) | (3.34) | (1.68) | 0.22 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.68% | 38.96% | 35.35% | 25.65% | |
Intangible Assets out of Total Assets |
0.45 | 0.40 | 0.38 | 0.37 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(1.64) | (4.10) | (2.65) | (4.87) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(606.74%) | (497.26%) | (502.99%) | (1,340.00%) | |
Free Cash Flow Yield |
(16.50%) | (116.71%) | (81.04%) | (120.60%) | |
Revenue per Share |
2.40 | 2.34 | 1.35 | 1.70 | |
Operating CF per Share |
0.00 | (0.08) | (0.30) | (0.03) | |
Capex per Share |
0.00 | (0.03) | 0.00 | (0.01) | |
Free Cash Flow per Share |
0.00 | (0.11) | (0.30) | (0.04) | |
Cash per Share |
0.13 | 0.14 | 0.04 | 0.02 | |
Shareholders Equity per Share |
4.76 | 2.34 | 1.20 | 0.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.76 | 2.34 | 1.20 | 0.98 | |
Free Cash Flow |
(0.02) | (0.56) | (2.82) | (0.45) | |
Working Capital |
(0.91) | 0.08 | (1.44) | (0.24) | |
Capital Expenditures |
(0.02) | (0.14) | (0.03) | (0.06) | |
Net Current Asset Value |
(12.21) | (15.92) | (16.59) | (15.39) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 3.81 | 5.71 | 7.43 | |
Average Payables |
3.14 | 4.13 | 5.67 | 5.20 | |
Average Inventory |
— | 13.35 | 13.92 | 12.99 | |
Average Assets |
29.59 | 49.30 | 53.00 | 53.28 | |
Average Common Equity |
11.22 | 4.68 | 19.08 | 19.32 |
Columns are period end dates